Denmark
· Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 30.11 billion. The enterprise value is 21.96 billion.
| Market Cap | 30.11B |
| Enterprise Value | 21.96B |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.69 million shares outstanding. The number of shares has increased by 16.16% in one year.
| Current Share Class | 70.69M |
| Shares Outstanding | 70.69M |
| Shares Change (YoY) | +16.16% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 53.33% |
| Float | 60.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.68 |
| PS Ratio | 540.61 |
| PB Ratio | 3.62 |
| P/TBV Ratio | 3.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.52 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.99 |
Financial Position
The company has a current ratio of 25.10, with a Debt / Equity ratio of 0.05.
| Current Ratio | 25.10 |
| Quick Ratio | 24.39 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.32 |
| Interest Coverage | -40.02 |
Financial Efficiency
Return on equity (ROE) is -21.27% and return on invested capital (ROIC) is -14.88%.
| Return on Equity (ROE) | -21.27% |
| Return on Assets (ROA) | -13.97% |
| Return on Invested Capital (ROIC) | -14.88% |
| Return on Capital Employed (ROCE) | -16.20% |
| Revenue Per Employee | 144,660 |
| Profits Per Employee | -3.08M |
| Employee Count | 335 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.40% in the last 52 weeks. The beta is 0.56, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -34.40% |
| 50-Day Moving Average | 494.65 |
| 200-Day Moving Average | 721.06 |
| Relative Strength Index (RSI) | 42.96 |
| Average Volume (20 Days) | 285,999 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 55.69 million and -1.19 billion in losses. Loss per share was -17.26.
| Revenue | 55.69M |
| Gross Profit | 52.01M |
| Operating Income | -1.42B |
| Pretax Income | -1.19B |
| Net Income | -1.19B |
| EBITDA | -1.41B |
| EBIT | -1.42B |
| Loss Per Share | -17.26 |
Balance Sheet
The company has 8.54 billion in cash and 394.64 million in debt, giving a net cash position of 8.15 billion or 115.28 per share.
| Cash & Cash Equivalents | 8.54B |
| Total Debt | 394.64M |
| Net Cash | 8.15B |
| Net Cash Per Share | 115.28 |
| Equity (Book Value) | 8.31B |
| Book Value Per Share | 117.53 |
| Working Capital | 8.60B |
Cash Flow
In the last 12 months, operating cash flow was -1.21 billion and capital expenditures -12.98 million, giving a free cash flow of -1.22 billion.
| Operating Cash Flow | -1.21B |
| Capital Expenditures | -12.98M |
| Free Cash Flow | -1.22B |
| FCF Per Share | -17.27 |
Margins
| Gross Margin | 93.39% |
| Operating Margin | -2,550.13% |
| Pretax Margin | -2,136.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.16% |
| Shareholder Yield | -16.16% |
| Earnings Yield | -3.94% |
| FCF Yield | -4.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 37.79.
| Altman Z-Score | 37.79 |
| Piotroski F-Score | n/a |